Clinical Data ECO 2026: tirzepatide shows potential for T1D treatment Pharmaceutical TechnologyDuring ECO 2026, a study was presented analysing the use of tirzepatide, a dual GIP and GLP-1 agonist, in treating type 1 diabetes (T1D).Metabolic & GLP-1Read full story pharminent May 15, 2026 Pharmaceutical Technology During ECO 2026, a study was presented analysing the use of tirzepatide, a dual GIP and GLP-1 agonist, in treating type 1 diabetes (T1D). Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidateNext: Biopharma industry endorses Pazdur for FDA commissioner role Related Stories Clinical Data Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs pharminent July 14, 2026 Clinical Data Major trial launched to explore GLP-1 benefit in dementia pharminent July 13, 2026 Clinical Data GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China pharminent July 10, 2026
